329 related articles for article (PubMed ID: 23018466)
21. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Moore S; Atwal S; Sachchithanantham S; Streetly M; Khan I; Percy L; Narat S; D'Sa S; Rabin N; Johnston R; Schey S; Yong K
Eur J Haematol; 2013 May; 90(5):420-5. PubMed ID: 23294279
[TBL] [Abstract][Full Text] [Related]
22. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
24. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
LoRusso PM; Venkatakrishnan K; Ramanathan RK; Sarantopoulos J; Mulkerin D; Shibata SI; Hamilton A; Dowlati A; Mani S; Rudek MA; Takimoto CH; Neuwirth R; Esseltine DL; Ivy P
Clin Cancer Res; 2012 May; 18(10):2954-63. PubMed ID: 22394984
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
27. Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
Osawa T; Naito T; Kaneko T; Mino Y; Ohnishi K; Yamada H; Kawakami J
Clin Biochem; 2014 Oct; 47(15):54-9. PubMed ID: 25011071
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Freytes CO; Toro JJ; Yeh RF; Stadtmauer EA; Ratanatharathorn V; Akpek G; Sahovic E; Tricot GJ; Shaughnessy PJ; White DJ; Rodriguez TE; Solomon SR; Yu LH; Zhao C; Patil S; Armstrong E; Smith A; Elekes A; Kato K; Reece DE
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1949-57. PubMed ID: 25139216
[TBL] [Abstract][Full Text] [Related]
30. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B; Kmieciak M; Perkins EB; Bose P; Baz RC; Roodman GD; Stuart RK; Ramakrishnan V; Wan W; Peer CJ; Dawson J; Kang L; Honeycutt C; Tombes MB; Shrader E; Weir-Wiggins C; Wellons M; Sankala H; Hogan KT; Colevas AD; Doyle LA; Figg WD; Coppola D; Roberts JD; Sullivan D; Grant S
Clin Cancer Res; 2014 Nov; 20(22):5652-62. PubMed ID: 25248382
[TBL] [Abstract][Full Text] [Related]
32. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J; Mizutani S; Shimura Y; Maegawa S; Nagoshi H; Chinen Y; Tatekawa S; Tsukamoto T; Mizuno Y; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Ann Hematol; 2015 Apr; 94(4):687-9. PubMed ID: 25209844
[No Abstract] [Full Text] [Related]
33. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ; Stinchcombe TE; Mitchell BS; Shea TC; Baldwin AS; Stahl S; Adams J; Esseltine DL; Elliott PJ; Pien CS; Guerciolini R; Anderson JK; Depcik-Smith ND; Bhagat R; Lehman MJ; Novick SC; O'Connor OA; Soignet SL
J Clin Oncol; 2002 Nov; 20(22):4420-7. PubMed ID: 12431963
[TBL] [Abstract][Full Text] [Related]
34. [Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma].
Wang YS; Ding SH; Wu F; Wang ZT; Wang QS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):529-32. PubMed ID: 24941833
[TBL] [Abstract][Full Text] [Related]
35. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
[TBL] [Abstract][Full Text] [Related]
36. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib.
Tan CRC; Abdul-Majeed S; Cael B; Barta SK
Clin Pharmacokinet; 2019 Feb; 58(2):157-168. PubMed ID: 29802543
[TBL] [Abstract][Full Text] [Related]
37. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models.
Williamson MJ; Silva MD; Terkelsen J; Robertson R; Yu L; Xia C; Hatsis P; Bannerman B; Babcock T; Cao Y; Kupperman E
Mol Cancer Ther; 2009 Dec; 8(12):3234-43. PubMed ID: 19934276
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
[TBL] [Abstract][Full Text] [Related]
39. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
40. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
